Pharmaceutical composition for alleviating or treating autosomal dominant polycystic kidney disease comprising dna methylation inhibitor

Abstract

In order to determine epigenetic variations of autosomal dominant polycystic kidney disease and functional association therebetween, the present inventors have subjected individuals with polycystic kidney disease and without polycystic kidney disease to analysis through methylation profiling in random fashion of the genome as a whole. Interestingly, in PKD1 and other genes associated with ion transport and cell adhesion, there was hypermethylation in the gene-body region, and the expression of these genes was down-regulated in polycystic kidney disease. In particular, in PKD1, there was hypermethylation in the polycystic kidney disease gene-body region, and this was associated with MBD2 (methyl-CpG-binding domain 2) protein binding. In addition, DNA methylation inhibitor treatment was accompanied by up-regulation of PKD1 expression and caused a delay in cyst formation in MDCK (Madin-Darby Canine Kidney) cells. This therefore demonstrates that, in the present invention, hypermethylation of PKD1 and regulator genes associated with cyst formation plays a decisive role in cyst formation and shows that the present invention can be used in therapeutic applications for autosomal dominant polycystic kidney disease.

Description

technical field [0001] The invention relates to a pharmaceutical composition for improving autosomal dominant polycystic kidney disease, which is characterized in that the composition contains a DNA methylation inhibitor. Background technique [0002] Autosomal dominant polycystic kidney disease (Autosomaldominant polycystic kidney disease: ADPKD) incidence rate is at least 1 in every 500-1000 more common genetic diseases. Compared with healthy people, autosomal dominant polycystic kidney will form more fluid-filled cysts on both sides of the kidney, and the kidney will be 4-8 times larger. So far, because there is no effective clinical treatment for polycystic kidney disease, most polycystic kidney disease will develop into end-stage renal disease (Gabow, 1993; Grantham, 1996). Cyst formation in human polycystic kidney disease is accompanied by cellular proliferation, increase, and cellular self-death of epidermal cells of the cyst. [0003] Although inherited in an autos...

AI Technical Summary

Problems solved by technology

However, there is no DNA methylation profiling analysis of the global epigenome or autosomal dominant polycystic kidney disease

[0005] Although many drugs for treating polycystic kidney disease have been developed so far, disappointing clinical results have been obtained due to the hindrance of negative feedback

Images